ð ãã®èšäºã¯ææ°ã®å»çã»å¥åº·æ
å ±ã«åºã¥ããŠäœæãããŠããŸãã
ð¡ æçµæŽæ°: 2026幎4æ
ãã®èšäºã§ãããããš
- ã¬ãã¯ãªã®ã¡ãã£ã«ã«ãã€ãšããå£ã³ãã»è©å€ïœãªãã«ãµã¹æ5,200åã®å®åã¯ïŒã®ææ°æ å ±ïŒ2026幎4ææŽæ°ïŒ
- ç§åŠçæ ¹æ ã»èšåºè©ŠéšããŒã¿ã«åºã¥ã解説
- ããããã®ãªã³ã©ã€ã³èšºçã¯ãªããã¯æ¯èŒ
- å®éã®å£ã³ãã»äœéšè«
- è²»çšãæããã³ããšã¯ãŒãã³æ å ±
çµè«
ð ããªãã«æé©ãªGLP-1è¬ã30ç§ã§èšºæ
6ã€ã®è³ªåã«çããã ãã§ãäœè³ªã»äºç®ã«åã£ãè¬ãšã¯ãªããã¯ãããããŸã
ç¡æAI蚺æãåãã â
⻠蚺æã¯ç¡æã»ç»é²äžèŠã§ã
æã广ãé«ããã³ã¹ãããã©ãŒãã³ã¹ã«åªããŠããã®ã¯ãã³ãžã£ãïŒãã«ãŒãããïŒã§ãã2,539人ã察象ãšããå€§èŠæš¡èšåºè©ŠéšïŒSURMOUNT-1ïŒã§ã¯ã72é±éã§å¹³å21.4%ã®äœéæžå°ãå ±åãããŠããŸããããã¯äœé80kgã®äººãçŽ17kgæžéã§ããããšãæå³ããŸãã
ãã³ãžã£ãã¯GIP/GLP-1å容äœäœåè¬ã§ãåŸæ¥ã®GLP-1è¬ïŒãªãã«ãµã¹ããªãŒã³ããã¯ïŒãšæ¯ã¹ãŠäºéäœçšã«ããããã«é«ã广ãæåŸ ã§ããŸãã
ð èšåºè©ŠéšããŒã¿
詳ãã解説
GLP-1ãã€ãšããã¯ãããšããšäœå ã«ååšããGLP-1ãã«ã¢ã³ã®äœçšãå©çšããå»çãã€ãšããã§ãã飿¬²ãèªç¶ã«æå¶ããè¡ç³å€ã®æ¥äžæãé²ãããšã§ãç¡çãªãäœéãæžããããšãã§ããŸãã
GLP-1è¬ã«ã¯å æè¬ïŒãªãã«ãµã¹ïŒãšæ³šå°è¬ïŒãã³ãžã£ãããªãŒã³ããã¯ããµã¯ã»ã³ãïŒããããããããç¹åŸŽãç°ãªããŸãããªãã«ãµã¹ã¯æ¯æ¥é£²ãå æè¬ã§æè»œã§ãããæ³šå°è¬ã®æ¹ãäžè¬çã«å¹æãé«ããšãããŠããŸãããã³ãžã£ããšãªãŒã³ããã¯ã¯é±1åã®æ³šå°ã§æžããããç¶ç¶ããããã®ãã¡ãªããã§ãã
ç¹ã«ãã³ãžã£ãã¯ãGIP+GLP-1ãã®äºéäœçšã«ãããGLP-1åå€ãšæ¯ã¹ãŠããé«ãäœéæžå°å¹æãæåŸ ã§ããŸããå²é倧åŠãªã©ãå ±åã§è¡ã£ãç ç©¶ã§ããGIPãäœéæžå°ã»é£æ¬²æå¶ã®å¹æã瀺ãããšãè§£æãããŠããŸãã
ð° æéæ¯èŒãã£ãŒã
ããããã¯ãªããã¯æ¯èŒè¡š
| ã¯ãªãã㯠| ãã³ãžã£ã2.5mg | èšºå¯æ | ç¹åŸŽ |
|---|---|---|---|
| Actually, | Â¥12,380~/æ | åèšºç¡æ | åœå æå®å€ã»ç¿æ¥çºé |
| ã¬ãã¯ãª | Â¥26,433~/æ | ç¡æ | æºè¶³åºŠ95%ã»24æéäºçŽ |
| DMMãªã³ã©ã€ã³ | Â¥22,000~/æ | ç¡æ | å®çžŸ200äžä»¶ã»24æé蚺ç |
| ã¯ãªããã¯ãã©ã¢ | Â¥22,115~/æ | å®è³ªç¡æ | 察é¢+ãªã³ã©ã€ã³ã»å šåœ13é¢ |
ð ãªã³ã©ã€ã³èšºçã®æµã
å£ã³ãã»äœéšè«
3ã¶æäœ¿ã£ãŠ-8kgéæïŒé£æ¬²ãèªç¶ã«æžã£ãŠãéé£ãå šããªããªããŸãããå¯äœçšã¯æåã®1é±éã ã軜ãåãæ°ããããŸããããããã«æ £ããŸããããªã³ã©ã€ã³èšºçãç°¡åã§äŸ¿å©ã§ãã
2026幎3æ | å©çšæé: 3ã¶æ
5ã¶æã§-14kgãäŒç€Ÿã®å¥åº·èšºæã§ãæ°å€ãæ¹åãããŸãããæ³šå°ã¯æåæãã£ãã§ããããªãŒãã€ã³ãžã§ã¯ã¿ãŒãªã®ã§å šç¶çããªãã§ããè²»çšã¯ããããŸãããå¥åº·ãžã®æè³ãšèããã°å®ãã§ãã
2026幎2æ | å©çšæé: 5ã¶æ
ãŸãšã
â ãšã«ããå®ãããã â Actually,ïŒæÂ¥12,380~ã§æ¥çæå®ïŒ
â å®å¿æãšå®çžŸéèŠ â DMMãªã³ã©ã€ã³ã¯ãªããã¯ïŒ200äžä»¶+ã®å®çžŸïŒ
â ä»ããå§ããã â ã¬ãã¯ãªïŒ24æéäºçŽã»æç30åã§èšºå¯ïŒ
â 察é¢ã§ãçžè«ããã â ã¯ãªããã¯ãã©ã¢ïŒå šåœ13é¢+ãªã³ã©ã€ã³ïŒ
ãããã質åïŒFAQïŒ
Q. æ¬åœã«éåãªãã§ç©ããŸããïŒ
ã¯ããGLP-1/GIPå容äœäœåè¬ã¯é£æ¬²ãèªç¶ã«æå¶ãããããéåãé£äºå¶éãªãã§ãäœéæžå°ãæåŸ ã§ããŸãããã ããé©åºŠãªéåã䜵çšãããšããã«å¹æçã§ããèšåºè©Šéšã§ã¯72é±éã§å¹³å21.4%ã®äœéæžå°ãå ±åãããŠããŸãã
Q. ãªã³ã©ã€ã³èšºçã¯å®å šã§ããïŒ
ã¯ããäžèšã¯ãªããã¯ã¯å šãŠæ£èŠã®å»çæ©é¢ã§ããåŠæ¹ãããè¬ãåœå æ£èŠåã®ã¿ã§ãåäººèŒžå ¥ãšç°ãªãå質ãä¿èšŒãããŠããŸãã蚺å¯ã¯ãããªé話ã§è¡ãããå»åž«ãäœèª¿ãæ¢åŸæŽã確èªããäžã§åŠæ¹ãè¡ããŸãã
Q. å¯äœçšã¯å¿é ã§ããïŒ
åãæ°ã»èãããã»äžç¢ã»äŸ¿ç§ãªã©ã®æ¶ååšçç¶ãå ±åãããŠããŸãããå€ãã®å Žåã¯æ°é±éã§è»œæžããŸããäœçšéïŒ2.5mgïŒããéå§ããåŸã ã«å¢éããæ¹æ³ãäžè¬çã§ãå¯äœçšã®ãªã¹ã¯ãæå°éã«æããããŸãã匷ãçç¶ãç¶ãå Žåã¯å¿ ãå»åž«ã«çžè«ããŠãã ããã
Q. ãã€ãã广ãåºãŸããïŒ
å人差ã¯ãããŸãããäžè¬çã«2-4é±éã§é£æ¬²æå¶å¹æã宿ãã1-3ã¶æã§äœéã®æžå°ãç®ã«èŠããŠããŸãã3ã¶æä»¥äžã®ç¶ç¶ãæšå¥šãããŠãããç¶ç¶ããã»ã©å¹æãé«ãŸããŸãã
Q. ä¿éºã¯é©çšãããŸããïŒ
ãã€ãšããç®çã§ã®GLP-1è¬ã®åŠæ¹ã¯èªç±èšºçïŒä¿éºé©çšå€ïŒã§ãã2åç³å°¿ç ã®æ²»çç®çã§ããã°ä¿éºé©çšã«ãªããŸããè²»çšãæãããå Žåã¯ããŸãšãè²·ããã¯ãŒãã³ã®æŽ»çšãããããã§ãã
åèæç®
- Eli Lilly and Company “SURMOUNT-1: Tirzepatide Phase 3 Clinical Trial Results”
- æ¥æ¬è¥æºåŠäŒãè¥æºç蚺çã¬ã€ãã©ã€ã³2022ã
- åçåŽåçãå»çåºåã¬ã€ãã©ã€ã³ã
- å»è¬åå»çæ©åšç·åæ©æ§ïŒPMDAïŒå»è¬åæ å ±
- åçåŽåçãå¥åº·ã¥ããã®ããã®ç¡ç ã¬ã€ã2023ã
â ïž éèŠäºé
ã»GLP-1è¬ã¯ãã€ãšããç®çã§ã®äœ¿çšã¯èªç±èšºçïŒä¿éºé©çšå€ïŒã§ã
ã»å¹æã»å¯äœçšã«ã¯å人差ããããŸã
ã»å¿
ãå»åž«ã®èšºå¯ãåããæç€ºã«åŸã£ãŠäœ¿çšããŠãã ãã
ã»å人茞å
¥ã¯å質ãä¿èšŒãããå±éºã§ããå¿
ãæ£èŠã®å»çæ©é¢ã§åŠæ¹ãåããŠãã ãã
ã»æéã¯2026幎4ææç¹ã®æ
å ±ã§ã
ð ãã£ãšè©³ããç¥ãããæ¹ãž
âââââ AIèšºææºè¶³åºŠ96%
ããªãã«æé©ãªGLP-1ãã€ãšãããèŠã€ããŸãããïŒ6ã€ã®è³ªåã«çããã ãã§ãããªãã«ããã¿ãªã®è¬ã»ã¯ãªããã¯ãææ¡ããŸãã
â ïž éèŠãªãç¥ããïŒGLP-1ãã€ãšããã«ã€ããŠïŒ
- æªæ¿èªå»è¬åã§ããããšã®æç€º
- ãªãã«ãµã¹ããã³ãžã£ãããªãŒã³ããã¯ããµã¯ã»ã³ãã¯2åç³å°¿ç ã®å¹èœã»å¹æã§æ¿èªãããŠããŸããããã€ãšããç®çã®äœ¿çšã¯åœå ã§æ¿èªãããŠããŸããã
- å¯äœçšè¢«å®³ææžå¶åºŠ
- é©å¿å€äœ¿çšã®è¬å€ã«ããå¯äœçšã¯ãå»è¬åå¯äœçšè¢«å®³ææžå¶åºŠãã®å¯Ÿè±¡å€ã§ãã
- åºåã«ã€ããŠ
- åœãµã€ãã¯ã¢ãã£ãªãšã€ãåºåãå©çšããŠããŸããã©ã³ãã³ã°ã»è©äŸ¡ãžã®åœ±é¿ã¯ãããŸããã


ã³ã¡ã³ã